脱水科斯托斯乳通过共同和不可逆转地准NLRP3有效地缓解炎症疾病
Qi Lv1, Yishu Zhang1, Juan Wang1
1Jiangsu Key Laboratory of Functional Substance of Chinese Medicine School of Pharmacy Nanjing University of Chinese Medicine Nanjing China.
脱水乳 (DCL) 是一种新型NLRP3炎症酶抑制剂. 它对NLRP3进行共性结合,破坏组合,并在炎症性疾病模型中显示治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- NLRP3炎症酶激活驱动炎症性疾病.
- 奥里多宁抑制NLRP3,但具有有限的抗炎作用.
- 脱水乳 (DCL) 通过虚拟查成为潜在的NLRP3抑制剂.
研究的目的:
- 研究DCL作为一种新型NLRP3炎症酶抑制剂.
- 为了阐明DCLNLRP3抑制的机制.
- 在NLRP3介导疾病模型中评估DCL的治疗疗效.
主要方法:
- 在实验室测试中,使用小鼠和人类巨细胞来评估IL-1β释放和caspase-1裂变.
- 生物化学研究以确定DCL的结合部位和对NLRP3的作用机制.
- 在体内研究中,使用大肠炎,克罗恩病,败血症休克和周周炎的小鼠模型.
主要成果:
- 在纳米分子度下,DCL强烈抑制IL-1β释放和caspase-1裂变.
- 通过在Cys280.0与NLRP3形成共价键,DCL破坏了NLRP3炎症酶组合和ASC寡合化.
- 在多种炎症性疾病的小鼠模型中,DCL表现出保护作用.
结论:
- DCL是NLRP3炎症酶的直接和强大的抑制剂.
- DCL的机制涉及NLRP3的共价修饰,抑制其与NEK7.7的相互作用.
- 在NLRP3炎症酶相关疾病中,DCL是一种有前途的治疗性化合物.
更多相关视频
09:04Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
